Fig. 2From: The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDSFlow chart. Group A: 109 exosome particles per dose, group B: 1010 exosome particles per dose, ICU intensive care unit, ITT intention-to-treat, mITT modified intention-to-treatBack to article page